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Stability of U-500 regular insulin in prefilled syringes
Abstract
Objective: To evaluate the stability of U-500 regular insulin in prefilled syringes stored under refrigeration
for up to 28 days.
Methods: U-500 regular insulin was drawn up in 1 mL insulin syringes in a clean, nonsterile environment to
emulate conditions of a patient’s home. Samples were assayed using a stability-indicating reverse-phase
high-performance liquid chromatography method immediately after preparation (day 0) and after 7, 14,
21, and 28 days under refrigeration. Before evaluation, all samples were diluted to a concentration of 40
units/mL in the starting mobile phase. Stability was determined by evaluating the percentage of the initial
concentration remaining at each time point.
Results: At least 93.3% of the initial U-500 insulin concentration remained throughout the 28-day study
period, with no statistically significant changes in the amount remaining. The percent of initial
concentration remained above 97% for the first 21 days of the study.
Conclusion: A prefilled syringe with U-500 regular insulin is stable for at least 28 days when stored under
refrigeration. These data are similar to those reported for U-100 regular insulin, indicating that prefilling
syringes with U-500 insulin is a safe and effective practice for patients who are unable to accurately draw
up their own point-of-care doses.
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Stability of U-500 regular
insulin in prefilled syringes
Melinda E. Lull, Justin J. Piacentino,
and Andrea N. Traina

Abstract
Objective: To evaluate the stability of U-500 regular insulin in prefilled syringes stored under refrigeration for
up to 28 days.
Methods: U-500 regular insulin was drawn up in 1 mL
insulin syringes in a clean, nonsterile environment to
emulate conditions of a patient’s home. Samples were
assayed using a stability-indicating reverse-phase
high-performance liquid chromatography method immediately after preparation (day 0) and after 7, 14, 21,
and 28 days under refrigeration. Before evaluation, all
samples were diluted to a concentration of 40 units/mL
in the starting mobile phase. Stability was determined
by evaluating the percentage of the initial concentration
remaining at each time point.
Results: At least 93.3% of the initial U-500 insulin
concentration remained throughout the 28-day study
period, with no statistically significant changes in the
amount remaining. The percent of initial concentration
remained above 97% for the first 21 days of the study.
Conclusion: A prefilled syringe with U-500 regular insulin is stable for at least 28 days when stored under refrigeration. These data are similar to those reported for
U-100 regular insulin, indicating that prefilling syringes
with U-500 insulin is a safe and effective practice for patients who are unable to accurately draw up their own
point-of-care doses.

U

-500 regular insulin is five times as concentrated
as the more common U-100 regular insulin. U-500
can be ideal for patients requiring large volumes of insulin, such as those with immune responses to insulin,
insulin receptor defects, or more commonly, severe insulin resistance secondary to obesity and long-standing diabetes. Clinicians are recognizing the benefits
of using highly concentrated insulin, and use of U-500
insulin increased by 137% between June 2007 and June
2009.1 Reducing the volume of solution injected also allows for more consistent absorption and improved glycemic control compared with use of large volumes of
less concentrated insulin preparations.2
Currently, U-500 insulin is the only highly concentrated insulin product available in the United States. It
also is the only insulin product that is not commercially
available in a prefilled pen injection device. Some patients with diabetes may lack the vision or dexterity to
accurately and safely draw up their own insulin doses
using a vial and syringe.3 This may be especially true
of patients requiring U-500 insulin, as this may be indicative of more severe or progressive diabetes given
their high degree of insulin resistance and large insulin
dose requirements. The consequences of patient error in
drawing up the correct dose can be much more grave
when using concentrated insulin, as a 0.1-mL variation
would be equivalent to a 50-unit change in dose rather
than the 10-unit variation if a U-100 concentration insulin was used. To minimize the risk of dosing errors such
as these, it is not uncommon for nurses, home health
aides, or other caregivers to draw up several days of
insulin syringes for a patient and leave them in a refrigerator for future use. It is imperative that pharmacists,
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especially those in the community setting, be able to
confidently counsel their patients on the ability to safely
prefill their insulin syringes with U-500 insulin. The
question of maintained efficacy with U-500 insulin in a
prefilled syringe is one that is occurring with growing
frequency given the increased use of U-500 insulin for
the management of diabetes.
The stability of U-100 insulin preparations in prefilled syringes has been well studied. Tarr et al.4 determined that U-100 regular insulin remains stable for
28 days at room temperature and under refrigeration.
Dunbar and Simon5 reported that U-100 regular insulin maintains immunologic and biologic potency for at
least 2 weeks. Zell and Paone6 found that U-100 regular
insulin is stable under refrigeration in polypropylene
syringes for at least 14 days. The previous two studies
did not examine stability past 14 days. Unfortunately,
no data currently exist regarding the duration of stability of U-500 regular insulin when stored in prefilled syringes. Because the stability of different concentrations
of protein solutions can vary over time,7 data regarding the stability of U-500 may differ from that of U-100;
therefore, an investigation of U-500 insulin is warranted.

Objective
The objective of this study was to determine if U-500
insulin is stable when stored in prefilled syringes at 4°C
for up to 28 days.

Methods

Preparation of samples
The stability U-500 insulin (Humulin R U-500 Regular Insulin, Eli Lilly, Indianapolis, IN; lot A849585A,
expiration February 2013) was evaluated after storage
in 0.3 mL 29 gauge × 0.5 in polypropylene insulin syringes (BD Ultra-Fine Needle insulin syringe, Becton
Dickinson, Franklin Lakes, NJ). Using careful technique
on a clean but nonsterile laboratory bench, 0.25 mL (125
units) of U-500 insulin was drawn into each syringe (n =
3 for each time point). Three samples were analyzed immediately to establish baseline (day 0) stability values.
The remaining 12 syringes were kept capped inside an
open tray in a laboratory refrigerator (3–5°C). At days
7, 14, 21, and 28, three of the stored syringes were removed for analysis. Sample also was drawn for a forced
degradation sample. In preparation for reverse-phase
(RP) high-performance liquid chromatography (HPLC)
analysis, each sample was diluted to an expected concentration of 40 units/mL in the starting mobile phase
according to previously published protocols.4
HPLC method
The RP-HPLC method previously described for use in
U-100 stability studies4,8 was adapted for use with modifications according to standard insulin HPLC protocols
Journal of the American Pharmacists Association

used by the column manufacturer (Ascentis Express
Peptide ES-C18 HPLC Columns, Sigma-Aldrich, St.
Louis, MO). The HPLC instrument included a constantflow solvent delivery system, variable volume injector,
degasser, autosampler, and an ultraviolet light detector
set to 214 nm (HPLC 2010A HT; Shimadzu Scientific Instruments, Marlborough, MA). The column used was
a C18 column (4.6 × 30 mm) with a 300-Å pore size and
5-µm particle size (BioBasic C18 column; Thermo Fisher
Scientific, Waltham, MA). Throughout the runs, the
column was maintained at 40°C. Shimadzu LC Solution software (version 1.25; Shimadzu Scientific Instruments) was used for data collection and processing.
The mobile phase was a linear gradient of mobile
phase A (deionized water and acetonitrile [90:10 v/v]
with 0.1% trifluoroacetic acid) and mobile Phase B (deionized water and acetonitrile [25:75 v/v] with 0.1% trifluoroacetic acid). A linear gradient was used between
two mobile phases, with a starting ratio of 75% A and
25% B, increasing to 40% B (60% A) over 15 minutes. The
ratio then was programmed to increase to 60% B (40%
A) from minute 15 to minute 20 to elute any remaining
material from the column. A rinse then was performed
with deionized water and methanol (1:1 v/v). Injections
of 10 μL samples were eluted at a rate of 1.5 mL/min,
with an average retention time of 4.8 ± 0.17 minutes.
Each of the three replicates at each time point was run in
duplicate on the HPLC. A standard curve of concentrations ranging from 0 to 100 units/mL was prepared to
establish the linearity of the peak area versus concentration. The standard curve was linear (r2 = 0.991) over the
concentration range. The inter- and intraday variability
of the RP-HPLC assay (as represented by coefficient of
variation) were 0.23% and 0.05%, respectively.
Stability-indicating ability of the method was determined through the assay of a forced degradation sample. The forced degradation sample was prepared by
adjusting the insulin to pH 2 with 10 N HCl and degrading the sample at 37°C for 96 hours. RP-HPLC analysis
was conducted for this degraded sample in duplicate
using the same method described above. The degraded
sample showed decreased area of the main peak (52.3%
remaining), and an unidentified degradation product
peak was observed approximately 0.7 minutes after
the insulin peak that is almost equal in area to the main
insulin peak. No significant peak was observed at this
time in other nondegraded samples.
Data analysis
The mean (±SD) area under the curve for insulin peak
1 was calculated. Mean values for days 7, 14, 21, and 28
were adjusted to a percent of the average day 0 value
(measured at 500 units/mL; diluted sample measured
at 40 units/mL). A one-way analysis of variance with a
Bonferroni post hoc test then was performed to detect
any statistically significant changes in insulin levels usj apha.org
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ing SigmaPlot version 11.2 (Systat Software, San Jose,
CA). P < 0.05 was considered statistically significant.

Results
Under RP-HPLC, the area under the curve for peak 1
(retention time 4.8 ± 0.17 minutes) represents pharmaceutically active U-500. Samples at all measured time
points retained at least 93.3% of the initial U-500 concentration (Table 1). Differences in percent of initial
concentration remaining between any time point were
not statistically significant (P = 0.130). This suggests a
minimal loss of product due to degradation. Degradation products, not observed after 28 days of storage, can
be seen in the forced degradation sample with a reduction in parent compound and the appearance of a second peak at 5.5 minutes.
Evidence in the literature is lacking regarding the
definition of stability of insulin in the absence of statistically significant changes. In clinical practice, insulin adjustments often are made in increments of 10% to 20%
of the given dose. Keeping this principal in mind, we
considered stability to be maintained if at least 90% of
the product remained at a given time point. Despite the
fivefold increase in insulin concentration, it appears that
U-500 insulin is at least as stable as U-100 insulin.4 At
least 93% of the initial product remains when prefilled
into syringes and refrigerated at 4°C with no statistically significant reductions in insulin concentration. A
slight drop in percent remaining at day 7 is not statistically different from any of the other values and remains
well above the 90% cutoff. The sample size gives adequate statistical power (>0.8); however, a larger sample
size may help normalize the values. In addition, future
studies should verify the sterility of U-500 insulin when
drawn and stored in nonsterile conditions, though the
sterility of U-100 insulin in prefilled syringes has been
established.4
The prescribing information for U-500 insulin states
that it must be used within 31 days of initial use or otherwise should be discarded.9 This should be taken into
consideration when preparing prefilled syringes of
U-500 insulin for subsequent storage. Additional consideration should be given to safely labeling and storing the syringes after they are prefilled because patients
often have multiple doses of insulin. In practice, we recommend storing each dose in a different container, with
each container in a different location in the refrigerator
(e.g., prebreakfast dose on the top shelf, prelunch dose
on the bottom shelf, predinner dose in the door). Caregivers also should be educated to label all insulin doses.
We typically recommend large white mailing labels
(approximately 2 in × 3 in). These labels can be attached
to the barrel of the syringe with the number of units
written in large print on one side and the meal written
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Table 1. Stability of U-500 Insulin in syringes at 4°C
Day
7
14
21
28

Percent initial concentrationa remaining
Mean ± SDb
97.848 ± 0.629
99.432 ± 3.857
99.906 ± 2.389
93.317 ± 2.379

Initial drug concentration = 500 units/mL.
Mean ± SD of three biological replicates (n = 3).

a

b

on the other. These measures are extremely important
to minimize the risk of the patient injecting the wrong
dose of their highly concentrated insulin and risking
hypo- or hyperglycemia. It also is imperative that on the
label, caregivers write in smaller print (for their use) the
date that the U-500 vial was originally opened and the
date the syringe was prefilled. These dates should be
checked regularly to ensure prefilled syringes are used
promptly and expired insulin is never administered by
the patient.

Conclusion
U-500 insulin in prefilled syringes stored at 4°C is
stable for up to 28 days. Prefilled syringes containing
U-500 insulin and stored at 4°C for up to 28 days can
be used confidently by caregivers for treating patients
with diabetes with severe insulin resistance who are
unable to independently manage a traditional vial and
syringe.
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